Fierce debate over Health Minister initiativeHealth Minister Jens Spahn's demand for additional power to decide on reimbursement of medical procedures has sparked a fierce debate, reported FAZ (p19 and 20) and Sueddeutsche Zeitung (SZ) on Saturday (p4), FAZ on Sunday (p20) and Handelsblatt on Tuesday (p8).
Health Minister appoints new expertsEconomist Beate Jochimsen and oncologist Christof von Kalle are the two new members of the health experts' advisory council (SVR Gesundheit), FAZ (p20) and Die Welt wrote on Monday (p20) (APMHE 61406).
German psychiatrists oppose drug prescription by psychotherapistsThe German association for psychiatry, psychotherapy and psychosomatics (DGPPN) has protested against a draft law prepared by the health ministry that would allow some psychotherapists to prescribe drugs, reported FAZ on Sunday (p16).
Plant for medical cannabis near DresdenGerman-Canadian pharma company Wayland is transforming a former slaughterhouse into a manufacturing site for cannabis pills, SZ wrote on Saturday (p32).
Executive exodus at AstraZenecaAstraZeneca's chief medical officer and head of development Sean Bohen is leaving the company, the latest in a series of resignations, wrote Handelsblatt on Tuesday (p47) (APMHE 61435).
Doubts over benefit of antidepressantsA meta-analysis of more than 500 studies on antidepressants conducted by Oxford university has proved a statistically significant benefit for these drugs compared to placebo, Die Welt reported on Sunday (p21).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.